LOS ANGELES, CA — (Marketwired) — 08/26/13 — (OTCQB: MMRF) ("MMR"), a leading provider of (PHRs), storage solutions and electronic document management and imaging systems for , today announced that as a result of the Expedited Patent Allowance Program referred to as the Patent Prosecution Highway ("PPH"), and following the issuance of U.S. patents to MMR for its anti-CD20 monoclonal antibodies, the Company has received confirmation of the filings of a divisional applic
LOS ANGELES, CA — (Marketwired) — 08/19/13 — (OTCQB: MMRF) ("MMR"), a leading provider of (PHRs), storage solutions and electronic document management and imaging systems for , today announced that as a result of China-s participation in the Patent Prosecution Highway Program and the issuance of patents to MMR for its anti-CD20 monoclonal antibodies in the U.S., the Company has received confirmation from China of the filing on August 15, 2013 of a divisional Chinese patent appli
LOS ANGELES, CA — (Marketwired) — 05/28/13 — (OTCQB: MMRF) ("MMR" or the "Company") today announced that Ivor Royston, M.D. has agreed to join the Company-s Board of Directors effective immediately. MMR-s Board of Directors voted unanimously to authorize management of the Company to extend an invitation to Dr. Royston to serve on the Board. MMR-s management and the Board believe it is in the best interest of the Company and its stockholders to have a director whose exper
LOS ANGELES, CA — (Marketwired) — 04/15/13 — (OTCQB: MMRF) ("MMR") today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the Company-s anti-CD20 monoclonal antibody assets, U.S. Serial No. 11/855,943, under the title, "Antibodies and Methods for Making and Using Them." This is the first U.S. patent to be granted for the Company-s anti-CD20 monoclonal antibodies, which have particular utility in fighting cancers. The anti-
